Fundraising Fox
Olema Pharmaceuticals
NASDAQ: OLMASan Francisco, US · Founded 2007 · 183 employees on LinkedIn · 9 known investors
Find your way into Olema Pharmaceuticals
Sign up to see every warm intro you have to Olema Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Olema Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance. It focuses on improving treatment outcomes for patients living with breast cancer.
Founders & leadership
Olema Pharmaceuticals was founded in 2007 by Cyrus L. Harmon, Ph.D. and Cyrus L. Harmon.
Investors · 9
How we know: Avoro Capital Advisors's portfolio page · funding news · Not right? Tell us
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: Lightspeed Venture Partners's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$527.4M disclosed across 5 rounds · 2018–2024
▶$250MraisedDec 2024 · 26 investors · PharmaceuticalsRule 506(b)
- David C. Myles, Ph.D.Executive Officer
- Sandra Horning, M.D.Director
- Scott GarlandDirector
- Sean Bohen, M.D., Ph.D.Executive Officer, Director
- Andrew RappaportDirector
- Graham Walmsley, M.D., Ph.D.Director
- Naseem Zojwalla, M.D.Executive Officer
- Yi LarsonDirector
- Cyrus L. Harmon, Ph.D.Director
- Shane KovacsExecutive Officer
- Ian ClarkDirector
- Gorjan Hrustanovic, Ph.D.Director
- Cynthia ButittaDirector
- Offering amount
- $250M
- Amount sold
- $250M
- Sales commissions
- $12.5M
- Placement agents
- Goldman Sachs & Co. LLC, LifeSci Capital LLC, Oppenheimer & Co. Inc., H.C. Wainright & Co., LLChow, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Jefferies LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$130MraisedSep 2023 · 12 investors · PharmaceuticalsRule 506(b)
- Yi LarsonDirector
- Shane KovacsExecutive Officer
- Cyrus L. Harmon, Ph.D.Director
- Ian ClarkDirector
- Graham Walmsley, M.D., Ph.D.Director
- Sandra Horning, M.D.Director
- David C. Myles, Ph.D.Executive Officer
- Andrew RappaportDirector
- Gorjan Hrustanovic, Ph.D.Director
- Naseem Zojwalla, M.D.Executive Officer
- Sean Bohen, M.D., Ph.D.Executive Officer, Director
- Cynthia ButittaDirector
- Offering amount
- $130M
- Amount sold
- $130M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$87.4MraisedOct 2020 · 27 investors · PharmaceuticalsRule 506(b)
- Peter KushnerExecutive Officer
- Kinney HornExecutive Officer
- David MylesExecutive Officer
- Shane KovacsExecutive Officer
- Graham WalmsleyDirector
- Andrew RappaportDirector
- Frank McCormickDirector
- Gorjan HrustanovicDirector
- Cyrus HarmonExecutive Officer, Director
- Ian ClarkDirector
- Cynthia ButittaDirector
- Sean BohenExecutive Officer, Director
- John MoriartyExecutive Officer
- Offering amount
- $87.4M
- Amount sold
- $87.4M
- Sales commissions
- $1.4M
- Placement agents
- Cowen and Company, LLC
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$53.9MraisedJun 2020 · 16 investors · PharmaceuticalsRule 506(b)
- Pamela KleinExecutive Officer
- Gorjan HrustanovicDirector
- Andrew RappaportDirector
- Graham WalmsleyDirector
- Cyrus HarmonExecutive Officer, Director
- Frank McCormickDirector
- Peter KushnerExecutive Officer
- Offering amount
- $55.4M
- Amount sold
- $53.9M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedAug 2018 · 13 investors · PharmaceuticalsRule 506(b)
- Andrew RappaportDirector
- David MylesExecutive Officer
- Marina BozilenkoDirector
- Peter KusherExecutive Officer, Director
- Frank McCormickDirector
- Cyrus HarmonExecutive Officer, Director
- Lawrence FritzDirector
- Gorjan HrustanovicDirector
- Andrei ManoliuDirector
- Offering amount
- $6.1M
- Amount sold
- $6.1M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Olema Pharmaceuticals do?
- Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance. It focuses on improving treatment outcomes for patients living with breast cancer.
- Who founded Olema Pharmaceuticals?
- Olema Pharmaceuticals was founded by Cyrus L. Harmon, Ph.D., Cyrus L. Harmon in 2007.
- Who are Olema Pharmaceuticals's investors?
- Olema Pharmaceuticals's investors include Avoro Capital Advisors, Bain Capital Life Sciences, Foresite Capital, Lightspeed Venture Partners, RA Capital, Wellington Management, Biotechnology Value Fund, Logos and 1 more.
- How much funding has Olema Pharmaceuticals raised?
- Olema Pharmaceuticals has disclosed $527.4M raised across 5 rounds.
- Where is Olema Pharmaceuticals headquartered?
- Olema Pharmaceuticals is headquartered in San Francisco, US.